These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1091 related items for PubMed ID: 24240560

  • 1. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB, Simunovic MP, Vandiver L, Aragon AV, Ysasaga JE.
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD.
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
    Rush RB, Rush SW, Aragon AV, Ysasaga JE.
    Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X, Hu Y, Sun X, Zhang J, Zhang M, Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB).
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [Abstract] [Full Text] [Related]

  • 9. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM, Chen E, Mariani A, Major JC, SAVE Study Group.
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [Abstract] [Full Text] [Related]

  • 10. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [Abstract] [Full Text] [Related]

  • 11. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration.
    Üney GÖ, Ünlü N, Acar MA, Hazirolan D, Altiparmak UE, Yalniz-Akkaya Z, Örnek F.
    Retina; 2014 Jan; 34(1):32-7. PubMed ID: 23751943
    [Abstract] [Full Text] [Related]

  • 12. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 13. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E, Rayess N, Ho AC, Regillo CD.
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [Abstract] [Full Text] [Related]

  • 14. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S.
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF.
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [Abstract] [Full Text] [Related]

  • 18. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodríguez FJ, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group.
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group.
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [Abstract] [Full Text] [Related]

  • 20. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.